Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 5/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.31 |
| ▸ | FEN1 | P39748 | 4/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24822802 | 0.85 | ALOX5AP (0.35) | TYK2AOC3CHRM2CHRM3ALOX5AP | |
| SCHEMBL15698663 | 0.82 | TYK2 (0.41) | TYK2AOC3CHRM2CHRM3TLR8 | |
| SCHEMBL30079490 | 0.82 | TYK2 (0.41) | TYK2AOC3CHRM2CHRM3TLR8 | |
| SCHEMBL24776721 | 0.78 | TYK2 (0.35) | TYK2AOC3CHRM2CHRM3ALOX5AP | |
| SCHEMBL29947295 | 0.78 | TYK2 (0.35) | TYK2AOC3CHRM2CHRM3ALOX5AP | |
| SCHEMBL24823659 | 0.76 | AOC3 (0.32) | TYK2AOC3CHRM2CHRM3BRD4 | |
| SCHEMBL24823032 | 0.75 | FYN (0.32) | TYK2AOC3CHRM2CHRM3BRD4 | |
| SCHEMBL24776196 | 0.75 | TYK2 (0.33) | TYK2CHRM2CHRM3BRD4BRD3 | |
| SCHEMBL17194892 | 0.74 | TLR8 (0.44) | TYK2CHRM2CHRM3BRD4BRD3 | |
| SCHEMBL24776105 | 0.74 | FYN (0.33) | TYK2AOC3CHRM2CHRM3ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210094948-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-01 | — | — | US | disclosed |
| US-10647713-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-17 | — | — | US | disclosed |
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210094948-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | TYK2 1/4885AOC3 4221/4885CHRM2 4803/4885 |
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | TYK2 1/4885AOC3 4221/4885CHRM2 4803/4885 |
| US-10647713-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | TYK2 1/4885AOC3 4221/4885CHRM2 4803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.